Loading...
OTCM
STME
Market cap44mUSD
Oct 06, Last price  
0.15USD
1Q
-52.23%
Jan 2017
-44.44%
IPO
25.00%
Name

Cell MedX Corp

Chart & performance

D1W1MN
OTCM:STME chart
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
-18.80%
Rev. gr., 5y
25.74%
Revenues
0
00042,62436,55736,5576,220095,82495,8246,0656,0652,762000
Net income
-895k
L+58.11%
-13,559-15,859-12,636-18,527-1,032,165-2,139,137-1,249,446-1,546,798-922,702-1,092,698-910,836-697,379-495,042-142,486-566,293-895,375
CFO
-312k
L+120.40%
0-19,249-12,636-9,778-316,811-421,572-754,059-449,427-307,542-925,844-560,432-450,591-272,209-145,898-141,600-312,081

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cell MedX Corp. is a biotechnology firm dedicated to identifying, developing, and marketing both therapeutic and non-therapeutic solutions aimed at individuals suffering from conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and various kidney-related ailments. The company's offerings include the eBalance Pro System, designed for clinical application by medical professionals, and the eBalance Home System, intended for personal use to promote general well-being and alleviate pain. Both systems are managed by the eBalance Console, a central control unit featuring three distinct pre-programmed microcurrent algorithms: wellness, pain management, and a dual mode. Originally established in 2010 as Sports Asylum, Inc., the company adopted its current name, Cell MedX Corp., in September 2014. Its operations are headquartered in Carson City, Nevada.

Key people

Chief Financial Officer, Treasurer, Secretary, Director · since 2016
Bradley S. Hargreaves
Vice President - Technology and Operations, Director · since 2017
Chief Medical Officer · since 2015
Director · since 2018
Frank Edward McEnulty
President, Director · since 2017
IPO date
Mar 11, 2013
Employees
Domiciled in
US
Incorporated in
US
Headquarters & legal address
123 W. NYE LN, SUITE 129
CARSON CITY, NV 89706
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑052025‑052024‑052023‑052022‑052021‑052020‑052019‑052018‑052017‑05
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT